Maxcyte SEC Filings

MaxCyte, Inc. reported that it has released preliminary unaudited financial results for the quarter and fiscal year ended December 31, 2025. The company furnished a press release dated January 12, 2026 as Exhibit 99.1 to a current report on Form 8-K under the item covering results of operations and financial condition. The information in this section and the exhibit is being furnished, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated by reference into other securities law filings.

MaxCyte, Inc. reported lower quarterly results as it navigates restructuring and integration of a recent acquisition. For the three months ended September 30, 2025, revenue was $6.8 million versus $8.2 million a year ago, driven by declines in instruments, consumables, and license activity. Net loss was $12.4 million compared to $11.6 million last year.

Nine-month revenue was $25.7 million versus $29.9 million in 2024, with operating cash use of $31.7 million. The company recorded $3.1 million in restructuring expense tied to a workforce reduction plan. Cash and cash equivalents were $13.0 million, with short‑term investments of $92.8 million and non‑current investments of $52.3 million as of September 30, 2025.

Customer concentration remained high: one customer represented 28% of Q3 revenue and 51% of accounts receivable. The SeQure Dx acquisition added capabilities in gene‑editing assessment; in Q3 it contributed $0.1 million of revenue and a $1.8 million net loss. Shares outstanding were 106.7 million as of November 7, 2025.

MaxCyte, Inc. furnished a current report announcing preliminary unaudited financial results for the quarter ended September 30, 2025 and reiterated its full‑year 2025 revenue guidance. The details are provided in a press release attached as Exhibit 99.1. The company stated that the information is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference except as expressly set forth by specific reference.

MaxCyte, Inc. disclosed anticipated costs tied to a workforce reduction plan. The company expects approximately $1.8 million for severance and healthcare continuation for directly employed personnel, $0.6 million for employees engaged through employer-of-record arrangements (covering severance, benefits, and statutory notice wages in jurisdictions such as Germany, France, and the United Kingdom), $0.4 million in wages and benefits required under Maryland's Mini-WARN Act (60 days' notice or pay in lieu), and $0.1 million in other costs including legal, consulting, and administrative expenses. In total, the disclosed near-term charge sums to $2.9 million, presented as estimates associated with implementing the Plan.

Hemrajani Rekha, a director of MaxCyte, Inc. (MXCT), reported the sale of 10,684 shares of the issuer's common stock on 06/25/2025 at a weighted average price of $2.0945 per share. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2025. After the reported transactions, the reporting person beneficially owned 39,893 shares, with ownership reported as direct.

The Form 4 indicates the sales occurred in multiple transactions at prices ranging from $2.07 to $2.1212. The reporting person offered to provide detailed breakdowns of share counts by price upon request. No derivative transactions or other securities changes are reported in this filing.

MaxCyte, Inc. filed a Form S-8 to register securities for its employee benefit plans, incorporating by reference its Annual Report on Form 10-K for the year ended December 31, 2024 (filed March 11, 2025), Quarterly Reports on Form 10-Q for periods ended March 31, 2025 and June 30, 2025, certain Form 8-Ks, and its Form 8-A description of common stock. The filing lists exhibits including the 2022 Equity Incentive Plan and the 2021 Employee Stock Purchase Plan, and names executive officers and directors such as Maher Masoud and Douglas Swirsky.

MaxCyte CFO Douglas J. Swirsky reported a non-derivative insider purchase on Form 4: he acquired 50,000 shares of MaxCyte common stock at $1.29 per share on 08/13/2025, increasing his direct beneficial ownership to 161,811 shares. The filing lists the transaction in Table I as a purchase and indicates no derivative securities were reported.

Masoud Maher, who serves as President, CEO and a Director of MaxCyte, Inc. (MXCT), reported the purchase of 75,000 shares on 08/13/2025. The Form 4 discloses the shares were bought in multiple transactions at prices ranging from $1.29 to $1.44, with a reported average price of $1.3722. Following these purchases, Mr. Maher’s direct beneficial ownership increased to 175,000 shares. The filing also states he will provide itemized per-price purchase details on request.

Erck Stanley C, a director of MaxCyte, Inc. (MXCT), purchased 100,000 shares of the company’s common stock on 08/13/2025. The Form 4 shows the purchases were coded as P (purchase) and were made at prices ranging from $1.29 to $1.44, with a reported price entry of $1.3722. After the transactions the reporting person directly beneficially owned 398,328 shares. The filer notes the shares were bought in multiple transactions and offers to provide a detailed breakdown of the number of shares bought at each price upon request. No derivative holdings are reported on the form.